233 related articles for article (PubMed ID: 33100053)
1. A sustained dual drug delivery system for proliferative vitreoretinopathy.
Xiao Y; Choi KS; Warther D; Huffman K; Landeros S; Freeman WR; Sailor MJ; Cheng L
Drug Deliv; 2020 Dec; 27(1):1461-1473. PubMed ID: 33100053
[TBL] [Abstract][Full Text] [Related]
2. Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.
Hou H; Nieto A; Ma F; Freeman WR; Sailor MJ; Cheng L
J Control Release; 2014 Mar; 178():46-54. PubMed ID: 24424270
[TBL] [Abstract][Full Text] [Related]
3. New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies.
Moon SW; Sun Y; Warther D; Huffman K; Freeman WR; Sailor MJ; Cheng L
Drug Deliv; 2018 Jan; 25(1):600-610. PubMed ID: 29461171
[TBL] [Abstract][Full Text] [Related]
4. Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.
Warther D; Xiao Y; Li F; Wang Y; Huffman K; Freeman WR; Sailor M; Cheng L
Drug Deliv; 2018 Nov; 25(1):1537-1545. PubMed ID: 29996687
[TBL] [Abstract][Full Text] [Related]
5. Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.
Hou H; Wang C; Nan K; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):557-66. PubMed ID: 26882530
[TBL] [Abstract][Full Text] [Related]
6. A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.
Hou H; Huffman K; Rios S; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2755-63. PubMed ID: 25829415
[TBL] [Abstract][Full Text] [Related]
7. Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.
Chhablani J; Nieto A; Hou H; Wu EC; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1268-79. PubMed ID: 23322571
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.
Wang C; Hou H; Nan K; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2014 Dec; 129():74-82. PubMed ID: 25446320
[TBL] [Abstract][Full Text] [Related]
9. A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate for proliferative vitreoretinopathy.
Kim JS; Beadle JR; Freeman WR; Hostetler KY; Hartmann K; Valiaeva N; Kozak I; Conner L; Trahan J; Aldern KA; Cheng L
Mol Vis; 2012; 18():1907-17. PubMed ID: 22876115
[TBL] [Abstract][Full Text] [Related]
10. Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.
Nan K; Ma F; Hou H; Freeman WR; Sailor MJ; Cheng L
Acta Biomater; 2014 Aug; 10(8):3505-12. PubMed ID: 24793657
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
Berger AS; Cheng CK; Pearson PA; Ashton P; Crooks PA; Cynkowski T; Cynkowska G; Jaffe GJ
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2318-25. PubMed ID: 8843916
[TBL] [Abstract][Full Text] [Related]
12. A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.
Chen M; Hou J; Tan G; Xie P; Freeman WR; Beadle JR; Hostetler KY; Cheng L
Drug Deliv; 2017 Nov; 24(1):1703-1712. PubMed ID: 29115885
[TBL] [Abstract][Full Text] [Related]
13. EIU in the rat promotes the potential of syngeneic retinal cells injected into the vitreous cavity to induce PVR.
Behar-Cohen FF; Thillaye-Goldenberg B; de Bizemont T; Savoldelli M; Chauvaud D; de Kozak Y
Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3915-24. PubMed ID: 11053294
[TBL] [Abstract][Full Text] [Related]
14. TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY.
Iglicki M; Zur D; Fung A; Gabrielle PH; Lupidi M; Santos R; Busch C; Rehak M; Cebeci Z; Charles M; Masarwa D; Schwarz S; Barak A; Loewenstein A;
Acta Diabetol; 2019 Oct; 56(10):1141-1147. PubMed ID: 31089929
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Ozurdex® (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy.
Kuo HK; Chen YH; Wu PC; Kuo YH
Ophthalmologica; 2015; 233(3-4):198-203. PubMed ID: 25721986
[TBL] [Abstract][Full Text] [Related]
16. Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations.
Rahimy MH; Peyman GA; Fernandes ML; el-Sayed SH; Luo Q; Borhani H
J Ocul Pharmacol; 1994; 10(3):561-70. PubMed ID: 7836865
[TBL] [Abstract][Full Text] [Related]
17. Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.
Hartmann KI; Nieto A; Wu EC; Freeman WR; Kim JS; Chhablani J; Sailor MJ; Cheng L
J Ocul Pharmacol Ther; 2013 Jun; 29(5):493-500. PubMed ID: 23448595
[TBL] [Abstract][Full Text] [Related]
18. Cell proliferation in human epiretinal membranes: characterization of cell types and correlation with disease condition and duration.
Oberstein SY; Byun J; Herrera D; Chapin EA; Fisher SK; Lewis GP
Mol Vis; 2011; 17():1794-805. PubMed ID: 21750605
[TBL] [Abstract][Full Text] [Related]
19. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
Kuo HK; Wu PC; Yang PM; Chen YH; Wu YC; Hu DN
J Ocul Pharmacol Ther; 2007 Feb; 23(1):14-20. PubMed ID: 17341145
[TBL] [Abstract][Full Text] [Related]
20. Blockade of endothelinergic receptors prevents development of proliferative vitreoretinopathy in mice.
Iribarne M; Ogawa L; Torbidoni V; Dodds CM; Dodds RA; Suburo AM
Am J Pathol; 2008 Apr; 172(4):1030-42. PubMed ID: 18310504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
